|Bid||19.10 x 3100|
|Ask||19.50 x 21500|
|Day's Range||19.11 - 19.78|
|52 Week Range||16.63 - 32.23|
|Beta (5Y Monthly)||1.72|
|PE Ratio (TTM)||212.67|
|Earnings Date||Feb 24, 2020 - Feb 28, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.81|
The S&P; 500 is trading for more than 20 times earnings, well above its 18.8 long-term average. But don't confuse this with a warning sign.
The U.S. Food and Drug Administration and other healthcare regulators are investigating whether diabetes drug metformin had contaminations of a cancer-causing chemical that prompted a recall of a commonly used heartburn medication this year. The move is part of the FDA's broader push to investigate a range of drugs for the presence of the carcinogen, known as N-nitrosodimethylamine (NDMA), with heartburn drug Zantac being recalled this year for fear it contained NDMA.
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]
Pfizer stock has tumbled, below other pharmaceutical stocks. Recent news has been upbeat with a drug approval and acquisitions. But the question remains: Is Pfizer stock a buy right now?
Shares of Lannett Company Inc. rallied 11% in premarket trading after it said a clinical trial for its experimental long-acting insulin biosimilar met the primary endpoints. Lannett and HEC Group are developing a biosimilar version of Sanofi's Lantus, which has long been the French drugmaker's top-selling drug. Mylan and Biocon are also expected to bring a Lantus biosimilar to market in 2020, although the U.S. application process has slowed since the Food and Drug Administration sent two complete response letters with corrective actions. Lannett's stock has jumped 78% year-to-date, compared to the S&P 500 , which is up 24%.
Acorda's (ACOR) lead MS drug Ampyra is hit by generic competition in the United States, which is hurting the company's top line of late. Parkinson's disease drug Inbrija seems an ideal replacement.
Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced the U.S. launch of Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin® (trastuzumab). Ogivri is available in a 420mg multi-dose vial and a 150mg single-dose vial in order to provide patient dosing and treatment flexibility. Ogivri was the first biosimilar trastuzumab approved by the U.S. Food and Drug Administration (FDA) and unanimously recommended by the FDA Oncologic Drugs Advisory Committee (ODAC). Ogivri is approved for all indications of Herceptin including for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma). Trastuzumab and biosimilar trastuzumab products contain a Boxed Warning for cardiomyopathy, infusion reactions, pulmonary toxicity and embryo-fetal toxicity.
Shares of generic drugmakers jumped Monday as speculation mounts about a series of legal settlements potentially nearing a resolution.
Shares of generic drugmakers are up in morning trading, with Mallinckrodt leading the pack as its stock rallied 15%. Teva Pharmaceutical Industries Ltd. is up 5%, Mylan up 4% and Endo International 4%. Bloomberg reported Monday morning that sources have said Teva and other drugmakers, including Sun Pharmaceutical Industries, are in talks with the Department of Justice to resolve allegations of price-fixing in the generic drug market. Separately, SVB Leerink analysts said this week that if plans for Endo, Mallinckrodt and Teva to enter into a "global opioid settlement framework" with state attorneys general go through, likely in the fourth quarter of 2019 or the first quarter of 2020, it would be a positive for those companies. "We could also see read-through for other opioid-levered names like Endo and Mallinckrodt," the analysts wrote in a Nov. 24 note.
Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will present at the Evercore ISI HealthCONx Conference in Boston on Tuesday, Dec. 3, 2019 at 11 a.m. ET.
Shares of Biogen rose 1.74% in morning trading after documents in a patent challenge brought by Mylan and Sawai show that Sawai and Biogen have settled. Sawai stock is up 1.6%; shares of Mylan are flat. Both companies had initially sought to challenge certain patents for Biogen's blockbuster multiple sclerosis drug Tecfidera. No other information about the settlement is available at this time. Bernstein analysts on Tuesday wrote: "Mylan has not settled but presumably, Biogen would not settle with Sawai if there were no chances of settling with Mylan as well." They rate Biogen as outperform. After a hearing last week, Evercore ISI analyst Umer Raffat had said that the case is likely "a very tough setup for Biogen." Tecfidera brought in $1.12 billion in sales in the third quarter of 2019, up from $1.09 billion in the like-period in 2018, making it Biogen's top-selling drug. Shares of Biogen are down 3.93% year-to-date. The S&P 500 is up about 24% year-to-date.
Shares of Biogen fell about 3% in afternoon trading. The Cambridge, Mass.-based biopharmaceutical company is facing a patent challenge from Mylan for its top-selling drug, multiple sclerosis treatment Tecfidera. A hearing was held Wednesday as part of the review; Evercore ISI analyst Umer Raffat wrote that "certain statements in the judge's institution decision suggested a very tough setup for Biogen on this IPR," but the hearing "appeared to have gone better than we anticipated." Tecfidera had a 3% bump in sales to $1.12 billion in the third quarter, up from $1.09 billion in the same period a year ago. Also, on Wednesday, the National Multiple Sclerosis Society came out in opposition to the pricing for Vumerity, a newly approved MS drug developed by Biogen and Alkermes . Biogen stock is down 9.2% for the year, while the S&P 500 is up about 23%.
Likelihood of a soon-to-be-signed U.S.-China trade deal, upbeat holiday season sales expectations and decent earnings have led the Nasdaq-100 ETF to a new high.
Mylan N.V. (MYL) and Pfizer Inc. (PFE) today announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris (pronounced ‘viǝ-trīs). Deriving its name from Latin, Viatris embodies the new company’s goal of providing a path—“VIA”—to three—“TRIS”—core goals: expanding access to medicines, leading by innovating to meet patient needs, and being a trusted partner for the healthcare community worldwide. “The name Viatris communicates the strength of our companies’ combined heritage and our shared goal to provide the highest-quality medicines to the most patients possible,” said Michael Goettler, Group President, Upjohn, who will serve as Chief Executive Officer of Viatris, as previously announced.
Generally, people turn to large-cap stocks when the future looks uncertain. It's almost cliche but has an element of truth to it. Large-cap stocks are generally more diversified, so if one part of the company's portfolio gets hit, it has more to make up for it. And some even have counter-cyclical components, specifically for this purpose.But that can get tricky, since focused companies usually are better at understanding the sector where they operate and can adjust to economic cycles. Either way, the point is being selective.This is plainly illustrated in the stocks below. These seven large-cap stocks are in sectors that are struggling now, and probably for a while to come. Some of the stocks have unique situations that turn good stocks in good sectors into stocks to avoid.InvestorPlace - Stock Market News, Stock Advice & Trading TipsEither way, steer clear of these stocks. To keep your portfolio moving in the right direction, adjust your strategy accordingly. Large-Cap Stocks: Occidental Petroleum (OXY)Source: Shutterstock Occidental Petroleum (NYSE:OXY) has not been doing well recently. As a matter of fact, the stock just hit a 14-year low this week.Much of the problem was its big buy of Anadarko Petroleum for $57 billion. At the time, it looked like a smart play on the domestic oil trend in the U.S. However, it's now a very heavy albatross.As we've sunk into a global recession -- all save the U.S. for now -- oil prices have been sinking. And if they're not sinking, they're certainly not rising. Even Saudi Arabia is talking about cutting production simply because there's already a glut in the market.And that's not to mention the fact that OXY likely paid top dollar for Anadarko, which is looking worse and worse. * 7 Beverage Stocks to Stock Up On Don't let its 8% dividend fool you. It's likely to get cut soon anyway. Schlumberger (SLB)Source: Valentin Martynov / Shutterstock.com Schlumberger (NYSE:SLB) is the world's largest oil services company. And after explaining why OXY is in such a pickle right now, it's a pretty similar story for SLB.If companies aren't drilling, then they don't need drilling equipment. When oil fields are slowing down or shutting down, they don't need oil services. When exploration slows, which is the bread and butter of SLB's business, the stock goes down.To be fair, SLB stock is treading water year-to-date. And its solid 5.6% dividend puts it above water. However, the stock is off 31% in the past 12 months and the future of the industry doesn't have a lot of sunshine.This isn't to say that this oil field legend is doomed. It's just going through a rough patch. But there's little point buying now when the trend still has more downside than upside. As I like to say, you couldn't pay me enough to invest my family's nest egg in any of these risky stocks. I prefer to invest in what I've dubbed "bulletproof stocks." Walgreens (WBA)Source: saaton / Shutterstock.com Walgreens (NASDAQ:WBA) seemed like the stock that was ushering in the consumer-facing side of modern healthcare in the U.S. and the United Kingdom.But things aren't looking so rosy now.It's not that the sector is under a great deal of pressure. This is a stock and company-specific issue. It seems any company that touches Rite Aid (NYSE:RAD) properties withers.WBA made a move for the entire company but was spurned by regulators. But it did acquire a portion of RAD shops. The hope was scaling up would bring more economies of scale and better margins. But it hasn't worked out that way yet. And just this week WBA announced that it was exploring the idea of going private. This was a shock -- and not a good one. The news sent the stock down further. * 7 Stocks to Sell Before They Roll Over While most analysts don't give the possibility much credence, it doesn't help the stock, which is now off 13% year-to-date and 28% for the year. Mylan (MYL)Source: sylv1rob1 / Shutterstock.com Mylan (NASDAQ:MYL) manufactured its first pill in 1966. Today, it's the second-largest generic drug manufacturers in the U.S.Just this year, it purchased Pfizer's (PFE) Upjohn unit that makes off-patent drugs. It has acquired a number of generic competitors over the years and continues its growth.But this side of the pharmaceutical business isn't what it used to be and growth by acquisition doesn't necessarily boost margins.Perhaps that was the logic in misclassifying its famous EpiPen so it could get some big bottom-line growth. But it was a lazy -- and illegal -- way to go about it, and now it has to pay the price with snowballing investigations, rising legal bills and growing numbers of analysts downgrading the stock.This is a falling knife you don't want to try catching. FedEx (FDX)Source: Antonio Gravante / Shutterstock.com FedEx (NYSE:FDX) is another mighty company that should be doing well in this expanding world of e-commerce. The problem is, the optimism got out ahead of the reality.Now that FDX is a global logistics company, it is more sensitive to global trends. And as the world's growth slows, so does FDX's.The other challenge is rising competition in both global and local markets. And in June of this year, FDX announced it wasn't renewing its express delivery service contract with e-commerce giant Amazon (NASDAQ:AMZN).Neither company walks away a winner in this decision and FDX has yet to announce a deal with another major retailer to fill the shoes of AMZN. But next-day delivery isn't cheap, and it's likely that FDX wasn't expecting the massive business the holiday season brings to help its earnings or margins at the end of the day. * 7 Earnings Losers That Were Hit Hard This Season Including its 1.6% dividend, FDX stock is about even year-to-date, but it's off 30% in the past year. And don't expect much upside until it fills the gap in AMZN revenue. Rather than throwing your money away here, you're much better off looking for stocks that exhibit the following characteristics: * Strong dividend growth * Stellar record of paying consistent dividends * An above-average yield (against the S&P 500) * Market-beating growth Posco (PKX)Source: testing / Shutterstock.com Posco (NYSE:PKX) is one of the top four steelmakers in the world. While it's based in South Korea, it also has joint operations in the U.S. with United States Steel (NYSE:X) in Pennsylvania and California.The story in this sector is once again the global slowdown. If fewer people are buying plants and equipment, or cars or other durable goods (or goods in general), then steel production falls.And when you're one of the biggest steel producers in the world, you can't keep your furnaces running if there's no demand for output.PKX is moving ahead with a lithium project in Argentina, but that isn't anywhere near completion. It's just good to know it's looking at supplementing its core market.Given the fact that global growth may remain slow for a while, there's no point in bargain hunting at this point. Deutsche Bank (DB)Source: Martynova Anna / Shutterstock.com Deutsche Bank (NYSE:DB) somehow remains the leading bank in Germany. And because of that, it's one of the key lenders to the European Union.Germany is known as the banker of Europe, given the fact that it's the largest economy on the continent and as a key EU partner, it runs the finances. When Greece was teetering, it was Germany that underwrote the loans to bail it out.But all that intertwined business has left it exposed on a number of levels to exploitation inside and outside the bank. It's constantly embroiled in scandals and hidden losses.It's Europe's version of too-big-to-fail bank. And since it has bankrolled the EU, it's even harder to shut it down or break it apart.Germany is now on the brink of recession and Europe isn't doing much better, especially as Brexit remains an issue. This is no time to add this kind of risk to your portfolio.To prepare for a shifting market, I suggest steps that every investor should take right now:* Follow the money: Buy stocks that are seeing massive cash infusions.* Protect your portfolio: Invest in market-beating stocks with my simple trick.* Go risk-off: Strong fundamentals are more paramount than ever.My stock-picking track record includes the following: * 274% gain in semiconductor stock Nvidia (NASDAQ:NVDA) * 134% gain in defensive plays * 123% gain in a personnel service stockTo learn how to invest in this shifting market, and to receive my top stock picks, click here.Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system -- with returns rivaling even Warren Buffett. In his latest feat, Louis discovered the "Master Key" to profiting from the biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Sell Before They Roll Over * 5 Beaten-Up Stocks to Buy That Could Be Saved By An Acquisition * 4 Startup Stocks Getting Smashed The post 7 Large-Cap Stocks to Give a Wide Berth appeared first on InvestorPlace.
Teva Pharmaceutical (TEVA) misses earnings estimate but beats the same for sales. The company increases the lower end of its 2019 sales and earnings guidance. Shares rise.
With the raging opioid crisis that has killed tens of thousands of Americans and injured millions more, it's understandable that state and local governments were not amused with big pharmaceuticals. Case in point is Teva Pharmaceutical (NYSE:TEVA). Over the past five years, Teva stock went from trading in high double digits down to single-digit territory.Source: JHVEPhoto / Shutterstock.com Granted, not everything involved opioids. A good portion of the damage done to Teva stock came from its ill-timed acquisition of Allergan's (NYSE:AGN) generic drugs business in 2016. Since then, the profit margins for generic drugs have fallen precipitously.This of course impacts Teva stock substantially. The underlying company is the world's biggest generic drug maker.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTypically, of course, Teva specializes in generics for high-priced medication that address severe symptoms or diseases. In other words, the company bridges the gap between a patient's ability to pay versus the help they need.However, the pharma company made the mistake of duplicating popular opioids. As a result, it fell under litigatory fire from multiple government bodies. In order to stop the bleeding in Teva stock, management secured a last-minute deal to settle all opioid-related lawsuits.Based on the deal's terms, Teva will donate $23 billion in opioid addiction treatment drugs -- a generic of the Suboxone drug -- and pay $250 million over 10 years. Naturally, the favorable agreement raised many eyebrows. * 7 Stocks to Sell Before They Roll Over Because the company is donating its generics, the basis of the $23 billion figure is suspect. By "inflating" the number via using the drug's list price -- which doesn't account for commonly given discounts -- the deal appears more favorable than it is.Still, despite the optics, this is a necessary move for the generics industry. Teva Rides a Blurry Line between Vindicator and VillainAlthough pharmaceuticals have strong long-term potential, I'm not the biggest fan of their products. Unless I'm having a health crisis, I prefer not to put anything unnatural in my body. And I'm especially not a fan when big pharma gets it wrong, like it did with the opioid crisis.While some people may want to see TEVA stock collapse entirely as poetic justice, I believe the settlement is fair. After all, the drug maker makes identical copies of branded (and comparatively expensive) medication. From my understanding, the company did not start the fire, but rather facilitated it.Whether Teva did so knowingly is up for debate. For what it's worth, the last-minute deal doesn't come with an admission of guilt.Granted, observers have a right to be skeptical. Nevertheless, I think we should consider Teva stock as a whole and not just in terms of the opioid crisis. Because here's where it gets blurry: Generics are lifesavers.I'm not making this comment to share an anecdotal tale. Just last year, the U.S. Food and Drug Administration approved a generic version of EpiPen. Designed to stop dangerous allergic reactions, EpiPen developer Mylan (NASDAQ:MYL) infamously raised the treatment's price by over 500%. The price hike was especially egregious because it negatively impacted children.Guess who provided the EpiPen generic? Teva.But does one right overturn a wrong? No, but that's not my point. Rather, generics serve a vital purpose in our complex and bloated healthcare system. According to the Association for Accessible Medicines, generics generated $265 billion in savings in 2017.With healthcare taking an increasingly larger chunk out of our wallets, the generic industry is simply irreplaceable. How to Approach Teva StockThere is absolutely no doubt that Teva stock is a speculative trade at this point. Beyond the opioid drama that has clouded pharmaceuticals, the company ballooned its debt while incurring declining revenue. That's not exactly the recipe for success.However, some good news has also appeared. Primarily, this came in the form of a contextually solid earnings beat. Although TEVA fell a bit short on per-share profitability, it beat revenue expectations. It's a small win on paper, but it confirms that the pharma is on the right track.Plus, as CBS News reported, drug prices have soared this year. Despite President Donald Trump's vow to rein in costs, healthcare remains a blight to the American people. It has caused some to skip out on expensive prescriptions or cross the border into Mexico for their medication.And while Democrats are well meaning with their proposal for free healthcare for all, let's face it: Money doesn't grow on trees. Thus, we may get our free healthcare but somehow, someway, we'll pay for it somewhere.And then we have Teva Pharmaceutical. Like a controversial comedian, it's vulnerable to a misfire. But with such vital need for reasonably priced medication, I don't think the perma-bear perspective makes sense.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dividend Stocks That Could Struggle to Continue Payout Hikes * 8 Consumer Stocks to Buy before Thanksgiving * 10 Stocks to Buy Regardless of Q3 Earnings The post With a Deal in Hand, Teva Stock Can Chart a Difficult Comeback appeared first on InvestorPlace.
NEW YORK, Nov. 07, 2019 -- Levi & Korsinsky notifies investors that it has commenced an investigation of Mylan N.V. (“Mylan” or “the Company”) (NASDAQ: MYL) concerning.